First Wave BioPharma Inc (FWBI)

[kzivann]

30 = 1 RS Friday. Watch.

FWBI

[m$teamworkotc]

https://ih.advfn.com/stock-market/NASDAQ/first-wave-biopharma-FWBI/stock-news/88919020/first-wave-biopharma-inc-announces-reverse-stock

[m$teamworkotc]

YES--TURN OUT DA LIGHTS
https://ih.advfn.com/stock-market/NASDAQ/first-wave-biopharma-FWBI/stock-news/88764606/prospectus-filed-pursuant-to-rule-424b3-424b3

[Smilin_B]

CD note issuance, a PIPE and/or the dreaded RS to reduce the OS so they can issue more shares

[Tom turtles]

Private placement at .15 cents...really ?

[Smilin_B]

True...

Not certain why anyone has been supporting the shares here because the company already said they are essentially closing up shop

[urge2surge]

Sad to say but most small bios are nothing more than an ATM paycheck for scientists and inept managerial. Anybody that knows anyone with oncology treatments, knows there isn't much integration in new treatments. I'll swing trade but won't invest. Justthe way it is.
Good luck..

[m$teamworkotc]

u saved me 5k with this post b fwiw..ty

[m$teamworkotc]

another nasdaq bomb...14 pennies...should be delisted and not allowed to r/s to maintain eligibility

[urge2surge]

Corporate got the wall street hot cattle prod on financing, but they'll live to give share holders additional bend Overs. A sign of truly inept management.

[m$teamworkotc]

turn out da lights

[m$teamworkotc]

SHORTS POUNDING THIS POS

[lecorb]

Roth Capital on May 26, 2022. The analyst firm set a price target for $9.00 expecting FWBI to rise to within 12 months (a possible 4066.67% upside). 2 analyst firms have reported ratings in the last year.


https://www.benzinga.com/quote/FWBI/analyst-ratings

[Pt3]

Gap fill lol

[glens0]

FWBI Healthcare stocks are surging

[urge2surge]

Haven't seen any. Could just be an over sold bounce but I still think the low outstanding shares here, sector, and previously mentioned points, could bode this for a white nite acquisition. Top side gaps as well. Worst case is a gap fill churn and burn to insolvency.
Some others I'm in or monitoring.

$ACOR
$SIOX
$AGRX.
$AFIB
$NDRA
$CETX
$SNGX
$SNPX

[Gurlik]

Maybe gap filing 0,43 today?

[Tom turtles]

Any news pre market ? Hit .32 cents already ?

[urge2surge]

That's one way to play it. Until the present chart technicals change, it looks to bounce. Will see what the market dictates.

[Smilin_B]

Sorry I'm only going by the fact that I read that the company was running out of cash and they were scheduled operations and shutting things down and letting employees go. It's best to just sit on the sidelines and see what happens and make a more informed decision once further updates arrive

[urge2surge]

Small outstanding shares, 5 million market cap, substantial NASDAQ listing value, NOLS, patent value, merger acquisition candidate, sizeable volume liquidity, open gaps.

[Smilin_B]

Is it me or didn't the company basically say they are shutting down operations? How can this possibly still be trading as high as it is trading? They are basically out of cash

[urge2surge]

Looks ready to launch and fill up the gaps.

[Tom turtles]

Nice job management......??

[Tom turtles]

Endless dumpfest

[m$teamworkotc]

in stocks only bud...hows my fav trader doing? buying here"?

[Smilin_B]

Indeed

[Tom turtles]

Going out of business sale

[Tom turtles]

Garbage !

[Tom turtles]

My God man.....they caught a lot of people today buying higher....

[Tom turtles]

I gave you a follow ..

[Tom turtles]

What a 1 year chart ..great job fellas....you holding this backstabbed ?

[Tom turtles]

Well that rally sucked !? Company just dumping

[Newc]

Volume too. Watching since premarket

[Backstabbed]

$FWBI - 2 gaps on the chart: $0.60 and $1.10

[Smilin_B]

I am ecstatic i stopped out of this one when it lost $1

Cant believe how low it's fallen but i guess this co is going to run out of cash, so im removing it from my watch list

Another blown up pharma...

[m$teamworkotc]

basically. and will be delisted

[m$teamworkotc]

i buy..they tank...simple ...im a huge fing looooooser

[Smilin_B]

So they are basically tightening up their spending and closing down certain initiatives?

[Smilin_B]

Wow I remember only this one in like the dollar 10 range and sold it at like $0.96. What the hell happened to it today?

[m$teamworkotc]

hedge funds are running the markets shorting everything like its the #otc

[Backstabbed]

That should be a good thing. Focus on where it matters most and cut spending

[m$teamworkotc]

ceo sent out a shareholder letter that they are cutting workforce and closing a france office to conserve cash

[Backstabbed]

I lost my shirt on this play

[Backstabbed]

I didn’t get what warranted this sell-off

[m$teamworkotc]

mms trying to steal oversold cheapies

[m$teamworkotc]

The diseases targeted by our drug candidates remain woefully underserved by current therapeutic options, which we believe provides First Wave BioPharma with the opportunity to address multiple large and growing patient populations. In the U.S., the ulcerative colitis market is currently estimated at $5 billion, while Crohn’s disease is estimated at $7.4 billion and EPI at $2 billion.

As a company, we continue to be driven by the mission of bringing relief to patients living daily with the often painful, dangerous, and discomforting symptoms inherent to GI disease, to protect their health and to restore quality of life.

Sincerely,
James Sapirstein
Chairman, President and CEO
First Wave BioPharma, Inc.

[m$teamworkotc]

While our FW-UP program is our most advanced, we are also developing formulations of niclosamide for pancolitis, a form of ulcerative colitis (FW-UC) and Crohn’s disease (FW-CD). To that end, earlier this week we announced the creation of an IBD Steering Committee comprised of four globally renowned experts in GI diseases, including UC and CD, to provide scientific and clinical guidance as we advance our programs.

Additionally, we continue to advance adrulipase for the treatment of exocrine pancreatic insufficiency (FW-EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP). We have made significant progress in identifying a microbead formulation delivery technology, which we believe will ensure the consistent delivery of the drug to the small intestine at therapeutically relevant levels. Our R&D team recently completed a white paper detailing the continued development of the microbead formulation and the benefits that it is expected to provide. A copy of that white paper may be accessed via the following link:

Adrulipase White Paper

[m$teamworkotc]

Overall, we remain confident in our inflammatory bowel disease (IBD) programs given niclosamide’s anti-inflammatory mechanism of action. In short, research indicates that IBDs, including ulcerative colitis (UC) and Crohn’s disease (CD), are driven by pathogenic Th17 cells, which release a cascade of local cytokines that in turn cause inflammation in bowel wall tissues. Niclosamide is known to disrupt the oxidative phosphorylation in the mitochondria of pathogenic Th17 cells in a manner that selectively induces apoptosis of pathogenic Th17 cells, overcoming their inherent resistance to cell death. By killing Th17 cells, niclosamide reduces inflammation and calms the gut, selectively killing pathogenic, inflammatory cells while leaving healthy cells untouched.

[m$teamworkotc]

While the top-line efficacy measure from the RESERVOIR trial did not show any anti-viral activity, the drug was well-tolerated without any serious adverse events. We believe this will continue to be the case for our ongoing clinical program of niclosamide (FW-UP) as a potential treatment for patients with ulcerative proctitis (UP) and ulcerative proctosigmoiditis (UPS), two forms of ulcerative colitis (UC). We look forward to the upcoming poster presentation at the 2022 Digestive Disease Week (DDW) Conference on data from a Phase 1 open label study of niclosamide as a potential treatment for patients with mild to moderate UP and UPS.